Furin-cleaved Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Is Active and Modulates Low Density Lipoprotein Receptor and Serum Cholesterol Levels
出版年份 2012 全文链接
标题
Furin-cleaved Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Is Active and Modulates Low Density Lipoprotein Receptor and Serum Cholesterol Levels
作者
关键词
-
出版物
JOURNAL OF BIOLOGICAL CHEMISTRY
Volume 287, Issue 52, Pages 43482-43491
出版商
American Society for Biochemistry & Molecular Biology (ASBMB)
发表日期
2012-11-08
DOI
10.1074/jbc.m112.380618
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Effect of a Monoclonal Antibody to PCSK9 on LDL Cholesterol
- (2012) Evan A. Stein et al. NEW ENGLAND JOURNAL OF MEDICINE
- An allosteric anti-hepsin antibody derived from a constrained phage display library
- (2012) R. Ganesan et al. PROTEIN ENGINEERING DESIGN & SELECTION
- Mechanistic implications for LDL receptor degradation from the PCSK9/LDLR structure at neutral pH
- (2011) Paola Lo Surdo et al. EMBO REPORTS
- PCSK9: an emerging target for treatment of hypercholesterolemia
- (2011) Christopher J Duff et al. EXPERT OPINION ON THERAPEUTIC TARGETS
- Role of the C-terminal domain of PCSK9 in degradation of the LDL receptors
- (2011) Øystein L. Holla et al. JOURNAL OF LIPID RESEARCH
- A Proprotein Convertase Subtilisin-like/Kexin Type 9 (PCSK9) C-terminal Domain Antibody Antigen-binding Fragment Inhibits PCSK9 Internalization and Restores Low Density Lipoprotein Uptake
- (2010) Yan G. Ni et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- In VivoEvidence That Furin from Hepatocytes Inactivates PCSK9
- (2010) Rachid Essalmani et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- A Two-step Binding Model of PCSK9 Interaction with the Low Density Lipoprotein Receptor
- (2010) Taichi Yamamoto et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Antibody-mediated disruption of the interaction between PCSK9 and the low-density lipoprotein receptor
- (2009) Christopher J. Duff et al. BIOCHEMICAL JOURNAL
- Pegylated Kunitz Domain Inhibitor Suppresses Hepsin-Mediated Invasive Tumor Growth and Metastasis
- (2009) W. Li et al. CANCER RESEARCH
- Fenofibrate treatment increases human serum proprotein convertase subtilisin kexin type 9 levels
- (2009) Jason S. Troutt et al. JOURNAL OF LIPID RESEARCH
- A new method for measurement of total plasma PCSK9: clinical applications
- (2009) Geneviève Dubuc et al. JOURNAL OF LIPID RESEARCH
- A proprotein convertase subtilisin/kexin type 9 neutralizing antibody reduces serum cholesterol in mice and nonhuman primates
- (2009) J. C. Y. Chan et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- PCSK9 as a therapeutic target of dyslipidemia
- (2008) Nabil G Seidah EXPERT OPINION ON THERAPEUTIC TARGETS
- Proprotein convertase subtilisin/kexin type 9 (PCSK9): Hepatocyte-specific low-density lipoprotein receptor degradation and critical role in mouse liver regeneration
- (2008) Ahmed Zaid et al. HEPATOLOGY
- Annexin A2 Is a C-terminal PCSK9-binding Protein That Regulates Endogenous Low Density Lipoprotein Receptor Levels
- (2008) Gaétan Mayer et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Characterization of novel mutations in the catalytic domain of the PCSK9 gene
- (2008) J. Cameron et al. JOURNAL OF INTERNAL MEDICINE
- PCSK9: a convertase that coordinates LDL catabolism
- (2008) Jay D. Horton et al. JOURNAL OF LIPID RESEARCH
- Molecular basis for LDL receptor recognition by PCSK9
- (2008) H. J. Kwon et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- PCSK9 and LDL cholesterol: unravelling the target to design the bullet
- (2008) Philippe Costet et al. TRENDS IN BIOCHEMICAL SCIENCES
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started